To access this element change to forms mode OFF
Grant Award View - GA217926
Dimethyltryptamine (DMT)-Assisted Psychological Therapy for...
GA ID:
GA217926
Agency:
Department of Health and Aged Care
Approval Date:
4-Nov-2021
Publish Date:
16-Feb-2022
Category:
Health and Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2025
Value (AUD):
$1,977,354.90
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
Dimethyltryptamine (DMT)-Assisted Psychological Therapy for Treatment-Resistant Major Depression, Alcohol Use Disorder, and Dual Diagnosis
Purpose:
Alcohol use disorder (AUD) and major depressive disorder (MDD) are disorders which commonly occur together, being associated with immense psychosocial impact. A potential novel treatment involves the use of the psychedelic formulation of the compound Dimethyltryptamine (known as 'DMT'). Research has revealed that DMT may alleviate depression, also having anti-addictive effects. We propose to conduct a clinical trial using DMT for adults with AUD and/or MDD.
GO ID:
GO Title:
MRFF - Clinical Trials Activity Initiative - 2021 Innovative Therapies for Mental Illness - Grant Opportunity
Internal Reference ID:
2021/MRF2014599
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED KINGDOM